Darunavir: pharmacokinetics and drug interactions.
作者： Richard M W Hoetelmans , Vanitha Sekar , David Back
DOI:
关键词:
摘要: Antiretroviral treatment (ART) for HIV is being scaled up rapidly in resource-limited countries. Treatment options are simplified and standardized, generally with one potent first-line regimen alternate recommended. Widespread drug resistance (HIVDR) was initially feared, but reports from countries suggest that initial ART programmes as effective resource-rich countries, which should limit if programme effectiveness continues during scale-up. interruptions must be minimized to maintain viral suppression on the long possible. Lack of availability appropriate second-line drugs a concern, additional accumulation mutations absence load testing determine failure. The World Health Organization (WHO) recommends minimum-resource strategy prevention assessment HIVDR WHO's Global Network HIVResNet provides standardized tools, training, technical assistance, laboratory quality assurance, analysis results recommendations guidelines public health action. National strategies focus assessments guide immediate action improve minimizing selection. Globally, WHO collects analyses data support evidence-based international policies guidelines. Financial provided by major organizations experts worldwide. As December 2007, 25 were planning or implementing strategy; seven report this supplement.
uq.edu.au参考文章(81)
Robert Colebunders, Moses Kamya, Fred Semitala, Barbara Castelnuovo, Elly Katabira, Keith McAdam, Free Antiretrovirals Must Not Be Restricted Only to Treatment-Naive Patients PLOS Medicine. ,vol. 2, ,(2005) , 10.1371/JOURNAL.PMED.0020276
Linda Tawfik, Stephen N. Kinoti, The impact of HIV/AIDS on the health workforce in developing countries ,(2006)
Tippawan Pankam, Sunee Sirivichayakul, Praphan Phanuphak, Donald Sutherland, Rachanee O-Charoen, Kiat Ruxrungtham, HIV drug resistance transmission threshold survey in Bangkok, Thailand Antiviral Therapy. ,vol. 13, pp. 109- 113 ,(2008)
G. Barungi, W. Nakahima, M. Jangano, E. Chidziva, M. Teopista, L. Chakonza, M. Nakazibwe, A. Mawora, G. Nassuna, C. Maweni, E. Chigwedere, M. Matongo, J. Komugyena, P. Khauka, P. Muygenyi, S. Chitsungo, A. Kambungu, T. Mupudzi, F. Sematala, H. Katabira, D. Masiira, C. Zawedde, C. Tumusiime, F. Mapinge, R. Warara, C. Muvirimi, N. Rutikarayo, T. Otim, K. Wangati, L. Generous, J. Chimanzi, R. Nairubi, E. Bulume, H. Chirairo, M. Namyalo, P. Ocitti, J. Sabiiti, A. Atwine, E. Katabira, D. Winogron, S. Murungi, A. Drasiku, C. Puddephatt, P. Mwesigwa, N. Mdege, G. Musoro, C. Twijukye, D. Yirrell, C. Kityo, F. Ssali, A. Muhwezi, N. Ngorima, B. Etukoit, R. Kasirye, H. Grosskurth, P. Kaleebu, P. Munderi, J. Machingura, S. Makota, C. Gilks, D. Nsibambi, M. Pascoe, C. Gale, G. Kabuye, D. Tumukunde, F. Lyagoba, R. Nalumenya, D. M. Gibb, M. Palmer, D. Bray, L. Vere, K. Taylor, A. Babiker, A. Coutinho, J. Oyugi, P. Naidoo, C. Hill, R. Massa, R. Enzama, J. Darbyshire, G. Mulindwa, A. Burke, S. Sheehan, A. Pozniak, A. McLaren, P. Hughes, C. V. Gale, A. Ronald, A. Reid, P. Mugyenyi, S. Bahendeka, D. Pillay, K. Boocock, K. Moyo, I. Machingura, J. Hakim, M. Phiri, M. Bassett, J. Leith, A. Latif, L. Mugarura, M. Aber, B. Amuron, J. M. Steens, F. Taziwa, R. Byaruhanga, E. Loeliger, H. Byakwaga, A. Zalwango, O. Mugurungi, J. Tukamushaba, A. Jamu, B. Gazzard, A. Mukose, A. S. Walker, S. Tugume, J. Nakiyingi-Miiro, D. Serwadda, J. Rooney, H. Kyomugisha, D. Atwine, H. Byomire, G. Tinago, M. Rauchenberger, L. Peto, J. Martin, J. Okiror, S. Mutsai, M. Ait-Khaled, A. Mugisha, T. Bakainyaga Grace, A. Chogo Wapakhabulo, L. Namale, I. Weller, J. Matenga, H. Wilkes, S. Mudzingwa, M. Chirara, E. Zalwango, B. Kikaire, J. H. Darbyshire, V. Robertson, Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa AIDS. ,vol. 20, pp. 1391- 1399 ,(2006)
Stephen D. Lawn, Guy Harling, Catherine Orrell, Robin Wood, Linda-Gail Bekker, Richard Kaplan, Matthew Mcnally, Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antiviral Therapy. ,vol. 12, pp. 83- 88 ,(2007)
Velephi Okello, Johanna Ledwaba, Visva Pillay, Diane E Bennett, Gugu Maphalala, Prudence Gwebu, Nomsa Mulima, Augustine Ntilivamunda, Yohannes Ghebrenegus, Themba Ginindza, Sandile Dlamini, Fabian Mwanyumba, Sibongile Mndzebele, Bonisile Nhlabatsi, Surveillance of transmitted HIV drug resistance in the Manzini-Mbabane corridor, Swaziland, in 2006. Antiviral Therapy. ,vol. 13, pp. 95- 100 ,(2008)
Simon Makombe, Nellie Wadonda-Kabondo, Eddie Limbambala, Anthony D Harries, Bethany L Hedt, Kelita Kamoto, Erik J Schouten, Mindy Hochgesang, John Aberle-Grosse, Early warning indicators for HIV drug resistance in Malawi. Antiviral Therapy. ,vol. 13, pp. 69- 75 ,(2008)
P. M. Pronyk, J. R. Hargreaves, J. D. Porter, B. Makhubele, K. A. Rowe, H. P. Hausler, Adherence to TB preventive therapy for HIV-positive patients in rural South Africa: implications for antiretroviral delivery in resource-poor settings? International Journal of Tuberculosis and Lung Disease. ,vol. 9, pp. 263- 269 ,(2005)
C. Kityo, P. Kaleebu, P. Munderi, D. Dunn, S. Tugame, D. Pillay, C. Gilks, V. Robertson, F. Lyagoba, J. Hakim, Emergence and evolution of drug resistance in the absence of viral load monitoring during 48 weeks of Combivir/Tenofovir within the DART Trial. ,(2007)
James McIntyre, Preventing mother-to-child transmission of HIV: successes and challenges. British Journal of Obstetrics and Gynaecology. ,vol. 112, pp. 1196- 1203 ,(2005) , 10.1111/J.1471-0528.2005.00716.X